Trial Profile
An Open Label, Safety, Tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD) and Preliminary Efficacy Study of Ruxolitinib When Applied to Patients With Plaque Psoriasis Involving 2 - 20% Body Surface Area (BSA)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Incyte Corporation
- 06 Oct 2009 New trial record.